))
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Manage episode 396148907 series 2838329
Контент предоставлен VJHemOnc. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией VJHemOnc или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions.
In this podcast, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, and Benjamin Derman, MD, University of Chicago, Chicago, IL, discuss several interesting topics in myeloma, including the challenges associated with sequencing anti-BCMA therapies, the prognostic value of circulating tumor cells (CTCs), and the growing role of quadruplet therapies in myeloma, with updates in this space from the 2023 ASH Annual Meeting.
200 эпизодов
Поделиться
